Cite
HARVARD Citation
Ascierto, P. et al. (2020). Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. Journal for immunotherapy of cancer. 8 (1), p. . [Online].